PMID- 28467427
OWN - NLM
STAT- MEDLINE
DCOM- 20170918
LR  - 20190208
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 12
IP  - 5
DP  - 2017
TI  - Comparison between 1-year outcomes of aflibercept with and without photodynamic 
      therapy for polypoidal choroidal vasculopathy: Retrospective observation study.
PG  - e0176100
LID - 10.1371/journal.pone.0176100 [doi]
LID - e0176100
AB  - Polypoidal choroidal vasculopathy (PCV) is characterized by polyp-like choroidal 
      neovascularization and a branching vascular network. Intravitreal aflibercept 
      injection (IAI) or photodynamic therapy (PDT) is used for treatment. We 
      retrospectively compared the 1-year outcomes of IAI monotherapy and its 
      combination with initial PDT for PCV. Twelve eyes with naive PCV received three 
      IAIs and a single PDT after the first IAI and as needed injection (combination 
      group); 11 eyes with naive PCV received three IAIs and as needed injections (IAI 
      group). Significant improvements in visual acuity after 2 months and in CRT after 
      1 month were maintained at 12 months in both groups (both P < 0.05); groups did 
      not differ significantly at any time point. CCT significantly reduced after 3 and 
      12 months in the combination group (both P < 0.05) but not in the IAI group. A 
      mean of 3.7 +/- 0.9 and 5.6 +/- 2.0 injections was administered to the combination 
      and IAI groups, respectively (P = 0.013). Within a 1-year period, combination 
      therapy was found to yield similar visual acuity and retinal structure 
      improvements and maintenance as IAI monotherapy while requiring fewer IAIs.
FAU - Takayama, Kei
AU  - Takayama K
AD  - Department of Ophthalmology, Nagoya University Graduate School of Medicine, 
      Nagoya, Japan.
AD  - Department of Ophthalmology, National Defense Medical College, Tokorozawa, Japan.
FAU - Kaneko, Hiroki
AU  - Kaneko H
AUID- ORCID: 0000-0003-0731-6465
AD  - Department of Ophthalmology, Nagoya University Graduate School of Medicine, 
      Nagoya, Japan.
FAU - Kataoka, Keiko
AU  - Kataoka K
AD  - Department of Ophthalmology, Nagoya University Graduate School of Medicine, 
      Nagoya, Japan.
FAU - Hattori, Kyoko
AU  - Hattori K
AD  - Department of Ophthalmology, Nagoya University Graduate School of Medicine, 
      Nagoya, Japan.
FAU - Ra, Eimei
AU  - Ra E
AD  - Department of Ophthalmology, Nagoya University Graduate School of Medicine, 
      Nagoya, Japan.
FAU - Tsunekawa, Taichi
AU  - Tsunekawa T
AD  - Department of Ophthalmology, Nagoya University Graduate School of Medicine, 
      Nagoya, Japan.
FAU - Fukukita, Hiroshi
AU  - Fukukita H
AD  - Department of Ophthalmology, Nagoya University Graduate School of Medicine, 
      Nagoya, Japan.
FAU - Haga, Fuminori
AU  - Haga F
AD  - Department of Ophthalmology, Nagoya University Graduate School of Medicine, 
      Nagoya, Japan.
FAU - Ito, Yasuki
AU  - Ito Y
AD  - Department of Ophthalmology, Nagoya University Graduate School of Medicine, 
      Nagoya, Japan.
FAU - Terasaki, Hiroko
AU  - Terasaki H
AD  - Department of Ophthalmology, Nagoya University Graduate School of Medicine, 
      Nagoya, Japan.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Observational Study
DEP - 20170503
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
RN  - 0 (Recombinant Fusion Proteins)
RN  - 15C2VL427D (aflibercept)
RN  - EC 2.7.10.1 (Receptors, Vascular Endothelial Growth Factor)
SB  - IM
MH  - Aged
MH  - Choroidal Neovascularization/*etiology/physiopathology
MH  - Female
MH  - Humans
MH  - Male
MH  - *Photochemotherapy
MH  - Receptors, Vascular Endothelial Growth Factor/*therapeutic use
MH  - Recombinant Fusion Proteins/*therapeutic use
MH  - Treatment Outcome
MH  - Visual Acuity
PMC - PMC5415056
COIS- Competing Interests: HT received personal fees from Bayer HealthCare, Novartis, 
      Santen, Wakamoto, and Pfizer, as well as research funding from Novartis, Santen, 
      Wakamoto, and Pfizer. There are no patents, products in development or marketed 
      products to declare. This does not alter our adherence to all the PLOS ONE 
      policies on sharing data and materials.
EDAT- 2017/05/04 06:00
MHDA- 2017/09/19 06:00
PMCR- 2017/05/03
CRDT- 2017/05/04 06:00
PHST- 2017/01/21 00:00 [received]
PHST- 2017/04/05 00:00 [accepted]
PHST- 2017/05/04 06:00 [entrez]
PHST- 2017/05/04 06:00 [pubmed]
PHST- 2017/09/19 06:00 [medline]
PHST- 2017/05/03 00:00 [pmc-release]
AID - PONE-D-17-02840 [pii]
AID - 10.1371/journal.pone.0176100 [doi]
PST - epublish
SO  - PLoS One. 2017 May 3;12(5):e0176100. doi: 10.1371/journal.pone.0176100. 
      eCollection 2017.